



The Office of the National Coordinator for
Health Information Technology
Health IT Advisory Committee

Conditions and Maintenance of Certification Requirements Task Force: Draft Recommendations to the HITAC

Denise Webb, co-chair
Raj Ratwani, co-chair

March 19, 2019



Agenda

- Task Force Members
- Task Force Charge
- Recommendations
 - » Conditions and Maintenance of Certification
 - » Updates to the 2015 Edition Certification Criteria
 - » Deregulatory Actions
- Questions and Feedback

Task Force Roster

Name	Organization	Role
Denise Webb	Individual	Chair
Raj Ratwani	MedStar Health	Chair
Carolyn Petersen	Individual	Member
Ken Kawamoto	University of Utah Health	Member
Sasha Termaat	Epic	Member
Leslie Lenert	Medical University of South Carolina	Member
John Travis	Cerner	SME

Conditions of Certification Task Force Charge

- **Overarching Charge:** Provide recommendations on the “API,” “real world testing,” and “attestations” conditions and maintenance of certification requirements; updates to most 2015 Edition health IT certification criteria; changes to the ONC Health IT Certification Program; and deregulatory actions.
- **Specific Charge:** Provide recommendations on the following:
 - “API,” “real world testing,” and “attestations” conditions and maintenance of certification requirements
 - Updates to the 2015 Edition certification criteria: “Standardized API for patient and population services,” “electronic health information export,” “electronic prescribing,” “clinical quality measures – export,” and privacy and security-related *attestation* criteria (“encrypt authentication credentials” and “multi-factor authentication”)
 - Modifications to the ONC Health IT Certification Program (Program)
 - Deregulatory actions related to certification criteria and Program requirements

Overarching Recommendation

Clarity on Rationale for Maintaining a “2015” Edition

- In review of the records retention requirements for ONC-ACBs but applicable to many sections of the proposed rule, the CMC TF questioned *why* ONC proposed to modify the 2015 Edition as opposed to creating a *new* Edition. There are broad-sweeping changes to the 2015 Edition as a result of this proposed rule. By not updating to a new Edition, users of the CHPL would be confused about which version of 2015 Edition is being referenced. Also, there are records retention implications for ONC-ACBs and Health IT developers when an Edition is continually modified rather than retired and replaced by a new Edition that may require retention for an inordinate amount of time that would not otherwise be required if a new Edition is established instead when there are significant modifications to an Edition by rulemaking.
- **Recommendation 1:** ONC should introduce a new Edition of certification rather than propose changes to the 2015 Edition.

Conditions and Maintenance of Certification

Real World Testing

- **Recommendation 2:** ONC should reconsider the due date for real world testing plans. The CMC TF recommends ONC provide more flexibility for deadline - avoid holidays, avoid overload for ONC-ACBs/federal government. The CMC TF recommends an alternative: anniversary date tied to the certification anniversary for the CEHRT being tested.
 - The CMC TF supports the idea of a pilot year and recommends having ONC-ACBs assess plans from pilot year then come up with a template for vendors to use.
- **Recommendation 3:** ONC should provide more clarity around care settings/venue to what the test plan must cover. The goal is to make minimum expectations clear in regards to applicable care settings and venues (which settings, sufficient number of settings) for the health IT product.
- **Recommendation 4:** ONC should provide guidelines or a template for a test plan. The template will help the process. The CMC TF supports the proposed pilot year and recommends that ONC-ACBs assess plans from the pilot year then provide a template for vendors to use addressing the minimum requirements for an acceptable test plan.

Real World Testing

- **Recommendation 5:** ONC should provide clarity around how successful real world testing is met: (1) continued compliance with certification criteria (including standards and code sets), (2) exchange in intended use settings, and (3) receipt and use of electronic health information in the certified EHR. The CMC TF reviewed and determined not all three elements are possible for *all* certification criteria proposed for real world testing.
- **Recommendation 6:** ONC should clarify and define the terms, “scenario” and “use case” and if these terms mean the same thing, then choose and use just one of these terms in the rule. ONC should also clarify the term “workflow” as it is used in real world testing.
- **Recommendation 7:** We recommend vendors be given discretion to incorporate permissible testing approaches, including, for example, automated testing and regression testing (also possibly automated).

Real World Testing

- **Recommendation 8:** ONC should provide clarification around testing the exchange of information, or about the use of the information. Testing the use of that information requires consideration of human factors and usability to understand whether the intended users efficiently and effectively use the presented information. When there are no end users of the product being tested, use-based testing would not be pertinent.
 - Use of data testing, if expected, would be pertinent to the receipt of data in the EHR. If the health IT developers are testing the use, they need to have the providers involved in the testing to determine if the providers can process and use that information when there is an exchange. The providers were not considered in the cost estimates for real world testing in the proposed rule preamble.
- **Recommendation 9:** ONC should clarify the expected involvement of providers and third parties to support the “real world” nature of the testing.
 - The CMC TF suggests providers using the certified technology should be involved in real world testing with the health IT developers, but the final rule needs good guidance on testing options that address the use of simulated data and address requirements for unidirectional versus bidirectional test cases. For example, the final rule should clarify whether the health IT developer is required to provide testing for both endpoints/sides in a bi-directional testing scenario.
 - If there is provider involvement, ONC should adjust provider estimates in the cost impact analysis in the proposed rule.

Real World Testing

- **Recommendation 10:** ONC should allow for flexibility for vendors with regard to real world testing where there is no difference in the testing approach, result or capability.

The CMC TF suggests:

- Common capability – test once across all settings and test cases if truly the same capability for the same requirement
- Unchanged capability – allow the vendor to attest to capabilities that remain unchanged from prior year
- Common requirement – test once if the requirement does not vary across all settings and test cases for requirements such as secure communication
- Production experience – clarify whether real world testing is required for what already has long-standing evidence and history of operating in real world production environments
- Clarify applicability of requirement for various practice and care settings. For example, clarify whether all of the named CDA/document types apply to every venue
- Attestation – allow for attestation instead of retesting

Real World Testing

- **Recommendation 11:** ONC should include a description of “measurement.” ONC should provide clarity about the role of measurement and specify for what kinds and for what purposes or proof points. After the pilot year, consider updating metric expectations: where the real world testing is of both interoperability and use of received data, consider there be at least one metric of interoperability and one metric of use, which might correspond with metrics of use used in safety enhanced design testing.
- **Recommendation 12:** ONC should elaborate and provide more clarity on the standards version advancement process when a version of standards is available under this process but does not yet have testing tools available yet to determine conformance. It is fairly clear vendors must factor all claimed versions of standards into their real world testing, but the final rule should clarify how the health IT developers are to address new versions for which tooling does not exist yet that they have attested to support and how the health IT developer and ONC-ACBs will judge or determine conformance. ONC should clarify whether testing will be required in a subsequent year’s real world testing plan once tooling is available or whether the health IT developer’s previous attestation is sufficient.

Real World Testing

- **Recommendation 13:** ONC should clarify the role and expectations of third parties over which the health IT developers have no control or authority over. For example, some third parties (immunization registries) and EHR developers are likely to receive many requests to participate in other parties' real world testing. While these entities can try to be helpful, they will not have unlimited resources to assist other groups. Clarify whether declining to participate in real world testing is considered to be information blocking. ONC should consider how reasonable protections can be provided for those who have limited resources and therefore are unable to participate in an unlimited set of tests. The rule should provide reasonable assurances to health IT developers who have tried to engage third parties in testing yet were not successful in getting their commitment to participate in testing.
- **Recommendation 14:** ONC should review and revise Regulatory Impact time estimates that would be required to ensure they are accurate and align to the clarified understanding of the real world testing proposal.

Attestations

- **Recommendation 15:** ONC should include a specific deadline at the middle of the year and the end of year/ beginning of year. It would provide flexibility for the ONC-ACBs to work with developers to get those in rather than specifying a predefined 14-day window of time which seems too prescriptive and subject to problems should the period of time fall during a holiday, or government closures, etc. ONC could specify, for example, that the deadline for the health IT developers to submit their semi-annual attestations to the ONC-ACB is the last Friday of January and July (this avoids holidays).

Application Programming Interfaces

- **Recommendation 16:** ONC should clarify and make an explicit statement of an acceptable relationship between the API Technology Supplier and the API User, or clarify what activities are expected or permitted to occur between the API Technology Suppliers and API Users. There are multiple relationships supported in this environment and this particular relationship is not sufficiently addressed in the proposed rule. Relationships prior to the involvement of an API Data Provider are particularly of interest.
- **Recommendation 17:** ONC should adopt solely FHIR Release 4 in the final rule for reference in proposed § 170.315(g)(10) (Option 4). This was recommended as the first normative version, supporting enhanced capabilities (such as bulk data), and not dividing the focus of the industry with multiple standards.
 - HITAC: Discuss considerations for FHIR Release 2.
- **Recommendation 18:** ONC should move forward with implementation specifications and implementation guides to ensure everyone is working from the same set of specifications as this would enhance interoperability and reduce implementation complexity and potentially cost. The CMC TF sees value in health IT developers harmonizing to a specified version/release.

Application Programming Interfaces

- **Recommendation 19:** ONC should address the legitimate and expected activity for SMART Guide to protect patient data with respect to providing persistent tokens to applications and their ability to keep the token confidential. The CMC TF recommends ONC further clarify. Someone will need to ascertain that API Users provided a persistent token are creating products that secure the token appropriately, but it is not clear who plays that role. ONC will need to clarify who it is and how the determination is made.
- **Recommendation 20:** The CMC TF has concerns over ONC not proposing a standard way for a request for multiple patients' data and recommends ONC specify a standard approach (which is available in FHIR R4). There are concerns because each developer could implement this differently and invest time in non-standard ways and then likely have to spend time/money transitioning to the standard way. The CMC TF also recognized there is an immediate need now to satisfy this type of request.
- **Recommendation 21:** The CMC TF was puzzled by requirements to update API documentation (6 months) prior to the requirement to update API capabilities (24 months). ONC should clarify what happens at 6 months and what happens at 24 months.

Application Programming Interfaces

- **Recommendation 22:** ONC should further clarify the requirements and expectations around the app registration condition of certification based on a number of issues the CMC TF identified regarding app registration. The CMC TF recommends clarification in the rule that would address the following:
 - What the practice of “registration” consists of and does not consist of and who is the party responsible for keeping a list of registered apps.
 - What “verifying the identity” of an API user consists of and does not consist of and who is the party responsible for performing this. If this is optional, specify that those who haven’t performed it are clearly excused from possible cases where API users misrepresent themselves.
 - What “vetting” an app (in contrast to verifying identity of a user) consists of and what falls outside the definition of vetting and who is the party responsible for vetting and who is prohibited from vetting. If vetting is optional and not performed, specify that those who haven’t performed it are clearly excused from any possible consequences attributable to poorly designed or malicious apps.
 - Identifying any tasks (such as an API Data Provider whitelisting a particular app for the first time or an API Data Provider endorsing particular apps) that fall outside of “registration,” “identity verification,” and “vetting.” Describe the tasks, and identify the parties that can and cannot perform them. If they aren’t performed, provide clarity that the party is not liable.

Updates to the 2015 Edition Certification Criteria

Electronic Health Information Export

- **Recommendation 23:** ONC should provide clarity around the scope of the EHI export. The CMC TF recommends it be limited to EHI collected and retained by the certified EHR technology and apply only to the EHI that is part of the legal medical record. Narrowing to the legal medical record was important in particular for research data stored in an EHR.
- **Recommendation 24:** ONC should clarify that the export process must accommodate manual review by the API Data Provider to comply with state/local laws prior to being released. A state may have laws prohibiting release of certain EHI to a patient and the EHI export process would need to accommodate compliance.
- **Recommendation 25:** ONC should include audit log data for transitioning systems use case (not for patient use case due to privacy of health system staff).
- **Recommendation 26:** ONC should not require specific timeframe restrictions for data export, due to complexity experienced by health IT developers complying with the time frame flexibility/timeframes in the View, Download, Transmit certification criterion.

Electronic Prescribing

- **Recommendation 27:** ONC should make e-Rx transactions that are not applicable to all settings and/or need piloting optional. If all transactions are required, this could jeopardize the timeline specified for availability/production use. The CMC TF recommends the revisions below:

(11) *Electronic prescribing.* (i) Enable a user to perform **whichever subset** of the following prescription-related electronic transactions **are relevant to their domain and system design and have been piloted and are ready for widespread use** in accordance with the standard specified in § 170.205(b)(1) and, at a minimum, the version of the standard specified in § 170.207(d)(3) as follows:

- (A) **Optional.** Ask mailbox (GetMessage).
- (B) Relay acceptance of transaction (Status).
- (C) Error response (Error).
- (D) Create new prescriptions (NewRx, **Optional**: NewRxRequest, **Optional**: NewRxResponseDenied).
- (E) Change prescriptions (RxChangeRequest, RxChangeResponse).
- (F) Renew prescriptions (RxRenewalRequest, RxRenewalResponse).
- (G) **Optional.** Resupply (Resupply).
- (H) Return receipt (Verify)
- (I) Cancel prescriptions (CancelRx, CancelRxResponse).
- (J) Receive fill status notifications (RxFill, **Optional**: RxFillIndicatorChange).

Electronic Prescribing

- (K) *Optional*. Drug administration (DrugAdministration).
- (L) *Optional*. Transfer (RxTransferRequest, RxTransferResponse, RxTransferConfirm).
- (M) *Optional*. Recertify (Recertification).
- (N) Request and receive medication history (RxHistoryRequest, RxHistoryResponse).
- (O) *Optional*. Complete risk evaluation and mitigation strategy transactions (REMSInitiationRequest, REMSInitiationResponse, REMSRequest, and REMSResponse).
- (ii) For each transaction listed in paragraph (b)(11)(i) of this section, the technology must be able to receive and transmit the reason for the prescription using the diagnosis elements in DRU Segment **if that segment is supported by the standard for that transaction**.
- (iii) *Optional*. For each transaction listed in paragraph (b)(11)(i) of this section, the technology must be able to receive and transmit the reason for the prescription using the indication elements in the SIG **Segment if that segment is supported by the standard for that transaction**.
- (iv) Limit a user's ability to prescribe all oral liquid medications in only metric standard units of mL (*i.e.*, not cc).
- (v) Always insert leading zeroes before the decimal point for amounts less than one and must not allow trailing zeroes after a decimal point when a user prescribes medications.

Clinical Quality Measures - Export

- Recommendation 28:** ONC should update the quality measurement proposal per the table below. ONC proposes that all products adopt both the CMS ambulatory IG for QRDA III and CMS inpatient IG for QRDA I. We see this as an important technical correction for quality reporting use cases.

	All PProducts
QRDA I import	Inpatient CMS IG
QRDA I EXport	Inpatient CMS IG
QRDA III export	Ambulatory CMS IG

Instead, the CMC TF recommends the adoption requirements look like:

	Products for Ambulatory Settings	Products for Inpatient Settings
QRDA I IMPORT	Generic	Generic
QRDA I EXPORT	Generic	Inpatient CMS IG
QRDA III export	Ambulatory CMS IG	Generic

- Recommendation 29:** The CMC TF agrees quality reporting using FHIR is a good aspirational direction to take and a future recommendation, but it is not ready today.

Privacy and Security-Related *Attestation* Criteria

- **Recommendation 30:** ONC should apply privacy and security attestations only to new certifications/new products after this rule is finalized, not to products already in widespread use, where the widespread publication of the attestation on these criteria might create a vulnerability and unintended consequences if malicious actors had this information about existing production systems.
- **Recommendation 31:** ONC should add a text box for developers to describe their yes/no attestations in certification. This would also help with clarity for use cases (login, signing EPCS, etc.).

Deregulatory Actions

Deregulatory Actions

Removal of Randomized Surveillance Requirements

- **Recommendation 32:** ONC should not remove the prohibition on consecutive selection of one health IT module (preserve (c)(6)). The goal is that if the proposed deregulation is implemented to remove the requirement on ONC-ACBs to conduct random surveillance, ONC-ACBs may still randomly surveil but cannot consecutively select the same HIT module for random surveillance more than once in a 12 month period. If through random surveillance, an ONC-ACB discovers non-conformance in a HIT module, they would still be able to follow up on the same HIT module within the 12 month period through its reactive surveillance authority.

Removal of Certain 2015 Edition Certification Criteria

- **Recommendation 33:** ONC should adopt a general principle of not duplicating data-capture criteria within the certification criteria (such as demographics) for data classes included in USCDI and based on this principle, the CMC TF recommends ONC consider other criteria, such as demographics, that could also be removed and do so in the final rule.